正在加载公司
Just reported
Q3 2026 results
From Harvard Bioscience's results release of 2026年11月10日; its quarterly report has since been filed.
Revenue
Actual
US$22.2M
+7.8% y/y
-2.3% q/qGuided
US$21.8M
midpoint
Within guide+1.8%EPS, GAAP
Actual
-US$0.58
Guided
—
No guide given
Operating income, GAAP
Actual
-US$1.2M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Harvard Bioscience is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Instruments and Supplies
Graded A or B and worth $2B or more: A first, then the largest.
ISRGIntuitive Surgical, Inc.US$153.8BA+
MDLNMedline Inc.US$51.9BA
ALCAlcon Inc.US$36.1BA
BLCOBausch & Lomb CorpUS$7.5BA-
ATRCAtriCure, Inc.US$2.9BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
GEHCGE Healthcare Technologies Inc.2026年10月28日CAGraded C, now A
基于 Harvard Bioscience, Inc. 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。
